Replimune Inc.   Report issue

For profit Phase 2
Founded: Woburn MA United States (2015)

Organization Overview

First Clinical Trial
2017
NCT03767348
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Replimune Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 2)

Carcinoma, Squamous Cell (Phase 2)

Melanoma (Phase 2)

Microsatellite Instability (Phase 2)

Skin Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 9
  • # of Trial APIs: 9